An evaluative in vitro investigation of the delivery of cytarabine with RGD decorated solid lipid nanoparticles. (17th November 2021)

• Record Type: Journal Article
• Authors: Van Eyssen, Shelly Roselyn; Kavaz, Doga
• Is Part Of: Journal of microencapsulation. Volume 38:Number 7/8(2021)
• Page Start: 546
• Page End: 558
• Publication Date: 2021-11-17
• Subjects: Solid lipid nanoparticles -- cytarabine -- kinetics -- drug delivery -- ligand; Microencapsulation -- Periodicals; Controlled release technology -- Periodicals; 615.19
• DOI: 10.1080/02652048.2021.1992028
• Languages: English
• ISSNs: 0265-2048

Abstract

Abstract: Aim: To synthesise cytarabine-loaded SLNs modified with the RGD peptide as a ligand, suitable for effective cancer therapy. Methods: SLNs were synthesised by the high shear, hot homogenisation technique. A 2 level 3 factor analysis was used in optimisation. Particle size, zeta potential, poly-dispersion index and surface morphology were measured. Drug encapsulation, drug release, release kinetics, nanoparticle stability and chemical structure were determined. LIVE/DEAD® Fluorescence Assay was used to qualify cytotoxicity and Tryphan Blue assay to quantify. Results: Cyt-SLNs exhibited a size of 161 ± 2.25 nm, a PDI of 0.49 ± 0.15 and a zeta potential of −19.8 mV. Entrapment fell at 88.87 ± 0.02% and release at 83.5 ± 0.95%. The in vitro release kinetics pointed towards a diffusion-based drug release mechanism. SLNs remained stable for 60 d. Cytotoxicity studies revealed that conjugation of the ligand with the RDG peptide resulted in a significant decrease in cell viability in both cell lines. Conclusion: Overall, the study suggests that RGD-SLN-cyt can be used for effective cancer therapy.